Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 14 papers were listed this time. Here's a few in our areas of research interest:
You JH, Tsui KK, Wong RS, et al. Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation. PLoS One. 2012;7(6):e39640. Epub 2012 Jun 22. PubMed PMID: 22745801.
Lee S, Anglade MW, Meng J, et al. Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin. Circ Cardiovasc Qual Outcomes. 2012 Jun 26. [Epub ahead of print] PubMed PMID: 22740012.
Davidson T, Husberg M, Janzon M, et al. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Eur Heart J. 2012 Jun 24. [Epub ahead of print] PubMed PMID: 22733833.
